Protocol for a randomized controlled trial examining multilevel prediction of response to behavioral activation and exposure-based therapy for generalized anxiety disorder. by Santiago, J et al.
UC San Diego
UC San Diego Previously Published Works
Title
Protocol for a randomized controlled trial examining multilevel prediction of response to 
behavioral activation and exposure-based therapy for generalized anxiety disorder.
Permalink
https://escholarship.org/uc/item/6cb012mk
Journal
Trials, 21(1)
ISSN
1745-6215
Authors
Santiago, J
Akeman, E
Kirlic, N
et al.
Publication Date
2020-01-06
DOI
10.1186/s13063-019-3802-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
STUDY PROTOCOL Open Access
Protocol for a randomized controlled trial
examining multilevel prediction of
response to behavioral activation and
exposure-based therapy for generalized
anxiety disorder
J. Santiago1, E. Akeman1, N. Kirlic1, A. N. Clausen4,5, K. T. Cosgrove1,3, T. J. McDermott1,3, B. Mathis1, M. Paulus1,2,
M. G. Craske6, J. Abelson7, C. Martell8, K. Wolitzky-Taylor6, J. Bodurka1,9, W. K. Thompson10 and Robin L. Aupperle1,2*
Abstract
Background: Only 40–60% of patients with generalized anxiety disorder experience long-lasting improvement with
gold standard psychosocial interventions. Identifying neurobehavioral factors that predict treatment success might
provide specific targets for more individualized interventions, fostering more optimal outcomes and bringing us
closer to the goal of “personalized medicine.” Research suggests that reward and threat processing (approach/
avoidance behavior) and cognitive control may be important for understanding anxiety and comorbid depressive
disorders and may have relevance to treatment outcomes. This study was designed to determine whether
approach-avoidance behaviors and associated neural responses moderate treatment response to exposure-based
versus behavioral activation therapy for generalized anxiety disorder.
Methods/design: We are conducting a randomized controlled trial involving two 10-week group-based interventions:
exposure-based therapy or behavioral activation therapy. These interventions focus on specific and unique aspects of
threat and reward processing, respectively. Prior to and after treatment, participants are interviewed and undergo
behavioral, biomarker, and neuroimaging assessments, with a focus on approach and avoidance processing and
decision-making. Primary analyses will use mixed models to examine whether hypothesized approach, avoidance, and
conflict arbitration behaviors and associated neural responses at baseline moderate symptom change with treatment,
as assessed using the Generalized Anxiety Disorder–7 item scale. Exploratory analyses will examine additional potential
treatment moderators and use data reduction and machine learning methods.
Discussion: This protocol provides a framework for how studies may be designed to move the field toward
neuroscience-informed and personalized psychosocial treatments. The results of this trial will have implications for
approach-avoidance processing in generalized anxiety disorder, relationships between levels of analysis (i.e., behavioral,
neural), and predictors of behavioral therapy outcome.
Trial registration: The study was retrospectively registered within 21 days of first participant enrollment in accordance
with FDAAA 801 with ClinicalTrials.gov, NCT02807480. Registered on June 21, 2016, before results.
Keywords: Generalized anxiety disorder, Depression, Behavioral activation, Exposure therapy, Cognitive behavioral
therapy, Functional magnetic resonance imaging
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Background
Anxiety disorders are the most common mental health
problem in the United States [1], and generalized anxiety
disorder (GAD) is the most common anxiety disorder in
primary care, with a lifetime prevalence rate of 6% [2]. It is
a debilitating disorder leading to significant individual and
socioeconomic burden with estimated annual costs of over
$1500 per patient [2, 3]. Its prognosis is poor, with only
58% of cases experiencing remission within 2 years [4].
GAD is accompanied by major depressive disorder (MDD)
in approximately 72% of cases, while MDD is accompanied
by GAD in 48% of cases [5]. GAD in those with depression
predicts poorer clinical outcomes and increased suicidal
ideation compared with those with depression alone [6].
Psychotropic medications (e.g., selective serotonin re-
uptake inhibitors [SSRIs]) and psychotherapeutic interven-
tions (e.g., cognitive behavioral therapy [CBT]) are both
effective evidence-based treatments for GAD [7, 8]. How-
ever, only 40–60% of patients experience improvement with
these treatments [9, 10], and 15–25% of those who improve
relapse within 1 year [9]. This creates both clinical and so-
cioeconomic challenges because these treatments are costly
and time-consuming [11]. By identifying cognitive, behav-
ioral, or neural factors that predict outcomes and can per-
haps be targeted in an individualized fashion, we can move
toward personalized approaches that assign each patient to
the optimal treatment for them.
The National Institute of Mental Health (NIMH) Re-
search Domain Criteria (RDoC) initiative seeks to improve
mental health assessment and treatment by enhancing un-
derstanding of basic psychological domains across mul-
tiple levels of analysis (e.g., neural systems, physiology,
behavior) [12]. Ideally, enhanced understanding of these
domains will inform personalized treatment approaches.
For example, if individual profiles of functioning across
positive valence (e.g., approaching reward), negative
valence (e.g., avoiding threat), or cognitive function (e.g.,
cognitive control) domains are identifiable, they could pre-
dict likelihood of success for various treatment approaches
[13]. To achieve this eventual goal of “personalized medi-
cine” [14], it is necessary to conduct clinical trials asses-
sing these multilevel domains of function, randomize
participants to comparator treatments, and examine com-
mon and unique predictors of treatment outcome.
Symptom severity, chronicity of symptoms, and comor-
bidity have been identified as potential predictors of GAD
treatment response [15], but these findings do not provide
specific targets for improving treatment effectiveness. The
neurocognitive investigation of GAD has focused on en-
hanced negative affect and threat detection, as well as
contradictory theories of either inadequate top-down pre-
frontal cortex (PFC) regulation (e.g., of amygdala) or PFC
overactivation supporting maladaptive cognitive strategies
(e.g., worry) [16]. There have been few neuroimaging
studies examining predictors of psychosocial treatment re-
sponse with GAD [17]. One study indicated that greater
frontal, temporal, and insular activation during emotion
reappraisal may predict better CBT response [18], but no
GAD study to date has examined the use of neuroimaging
to uniquely predict outcomes of two effective but diver-
gent interventions.
Anxiety disorders have been hypothesized to arise
from conflicting motivations to approach or avoid anxio-
genic situations that also contain potential gains, leading
to chronic distress, uncertainty, and use of maladaptive
coping mechanisms (i.e., avoidance, worry) [19, 20]. Ani-
mal paradigms thought to be relevant for GAD rely
heavily on approach-avoidance conflict (AAC) (such as
Vogel or Geller-Seifter conflict test, in which a behavior
is associated with both rewards, e.g., food pellet, and
punishment, e.g., shock) [21, 22]. We developed a hu-
man AAC task [23, 24] for use in functional magnetic
resonance imaging (fMRI) work, and we have shown
that approach behavior was linked to caudate and anter-
ior cingulate cortex activation, whereas difficulties arbi-
trating conflict were linked to self-reported anxiety and
dorsolateral prefrontal cortex (dlPFC) activation. Given
that GAD treatments typically focus on decreasing cog-
nitive and behavioral avoidance [25], the ability to suc-
cessfully arbitrate conflict (make decisions to approach
or avoid) could theoretically contribute to propensity for
treatment response. MDD has been associated with dys-
function in both reward and threat processing [26], and
MDD treatments often focus on increasing meaningful
engagement in rewarding or pleasurable activities [27].
Thus, approach-avoidance processing is likely important
in understanding treatment for the clinical presentation
of GAD with or without comorbid depression.
Herein we present the protocol of an ongoing study
designed to address the need for identifying moderators
of GAD treatment response. This protocol explores
multilevel moderators (self-report, behavioral, and neu-
roimaging) of response to exposure therapy (EXP) [25,
28] versus behavioral activation (BA) [29]. These inter-
ventions were chosen due to their (1) likelihood of
being effective for GAD and (2) specific and unique
functional targets relating to RDoC domains (i.e., avoid-
ance/threat targeted by EXP versus approach/
reinforcement processing targeted by BA; see Fig. 1).
We focused on the following aims:
1. Examine relationships among multilevel approach-
avoidance behavior and neural responses and base-
line GAD symptom severity
2. Examine how multilevel approach-avoidance be-
havior and neural responses moderate individual-
ized response to exposure-based therapy versus
BA for GAD
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3. Identify the changes in approach-avoidance pro-
cesses that relate to EXP- versus BA-elicited symp-
tom improvement
Methods/design
This protocol was written using the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
guidelines, and the SPIRIT checklist is provided in Add-
itional file 2. The protocol is part of an ongoing, random-
ized (two-condition), single-center (Laureate Institute for
Brain Research [LIBR], Tulsa, OK, USA), controlled trial
examining multilevel predictors of response to EXP versus
BA for GAD. The study is currently recruiting and is regis-
tered with ClinicalTrials.gov (identifier NCT02807480;
registration date June 21, 2016). No amendments have
been made to the protocol since original submission to
ClinicalTrials.gov. The study is funded by the National
Institute of Mental Health (grant K23MH108707; Robin L.
Aupperle [RLA], principal investigator [PI]) and the Wil-
liam K. Warren Foundation. Interventions include 10
weeks of manualized, group-based BA or EXP therapy.
Groups of 8-10 participants are randomized altogether to a
therapy group (randomization conducted in blocks of 4; se-
quence generated by RLA). Participants are kept blind to
their intervention condition until completion of all baseline
assessments; outcome assessors are partially blinded (see
further description in Additional file 1). Primary pre-
dictor variables of interest are assessed using the
approach-avoidance task (AAT) and the AAC task,
whereas the primary outcome measure is the GAD-7.
Secondary outcome measures include the Sheehan Dis-
ability Scale [30], NIH Patient-Reported Outcomes
Measurement Information System anxiety and depres-
sion scales [31], Beck Depression Inventory-II (BDI-II)
[32], and Penn State Worry Questionnaire [33].
The overall study protocol is presented in Fig. 2. Screen-
ing assessments confirm exclusion and inclusion criteria
for the study; baseline assessment includes self-report,
behavioral, biological, and neuroimaging assessments.
After baseline assessment, individuals are randomized to
Fig. 1 Approach-avoidance conflict model that provided the bases for the current study protocol, aims, and hypotheses. As illustrated, both the
fear or avoidance system and the reward/approach system are considered important in eliciting conflict and anxiety. Conflict arbitration requires
appropriate balancing of both approach and avoidance drives. In the current protocol, approach and avoidance behaviors are defined by
approach-avoidance test (AAT) bias scores; conflict arbitration is defined by reaction time during the approach-avoidance conflict (AAC) trials. For
brain responses, we focus on the AAC task and extract percentage signal change (PSC) from a priori regions of interest: (1) approach: left caudate
(reward versus no-reward outcome), (2) avoidance: right amygdala (negative versus positive affective outcome), and (3) conflict: right dorsolateral
prefrontal cortex (dlPFC; conflict versus nonconflict decisions). Exposure-based therapy was included as a treatment that primarily targets
avoidance or threat processes, whereas behavioral activation was included as a treatment that primarily targets approach or reward systems
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EXP or BA treatment, during which weekly self-report
symptom measures are obtained. After treatment, partici-
pants repeat baseline assessments. Self-report symptom
measures are repeated at 3 and 6 months following treat-
ment. Research is conducted ethically in accordance with
the World Medical Association Declaration of Helsinki.
Research personnel trained in human subject research ob-
tain written informed consent from each participant prior
to completing any research procedures. The consent form
for the study is included in Additional file 5.
Participants
Projected enrollment is 100 treatment-seeking individuals
meeting Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition (DSM-5), GAD criteria [34] over a 5-
year period (April 2016–April 2021), recruited from com-
munity mental health clinics and the general community
through electronic and print advertisements. Participants
must be 18–55 years old, have sufficient English proficiency
to understand study procedures, and meet DSM-5 criteria
per the Mini International Neuropsychiatric Interview
(MINI 7.0) for GAD and score > 7 on the Overall Anxiety
Severity and Impairment Scale [35]. Participants are ex-
cluded for the following reasons: (1) severe depressive
symptoms (Patient Health Questionnaire-9 score > 17) and/
or suicidal ideation with intent or plan, to decrease safety
concerns and help ensure that GAD was the primary cause
of impairment; (2) history of substance use disorder in the
past 6 months; (3) meeting diagnostic criteria for psychotic,
bipolar, obsessive-compulsive, or eating disorders; (4) mod-
erate to severe traumatic brain injury or other neurocogni-
tive disorder; (5) severe or unstable medical conditions, (6)
magnetic resonance imaging (MRI) contraindications, such
as metal or metallic devices in the body; (7) noncorrectable
vision or hearing problems; and (8) current use of psycho-
tropic medications that could affect brain function (e.g., an-
xiolytics, antipsychotics, or mood stabilizers). Participants
reporting current use of antidepressants (SSRIs) are in-
cluded as long as the dose has been stable for 6 weeks prior
to enrollment. Inclusion/exclusion criteria are meant to
decrease potential confounders while also supporting
generalizability of results to GAD patient populations in the
community.
Intervention
Both BA and EXP treatments consist of manualized, ten-
session interventions and are delivered in a group format
for 90min per week. For each group, participants are pro-
vided a binder to accompany the intervention, including
outlines of each session, basic descriptions of concepts,
and “homework” worksheets. Brief descriptions of each
intervention are provided below and in Table 1. Descrip-
tions of treatment compliance assessments and strategies
are provided in Additional file 1.
BA
BA is a recognized efficacious treatment for MDD [36]
and is based on the premise that negative or stressful life
Fig. 2 Schedule of enrollment, interventions, and assessments. This figure displays the assessments or interventions completed for screening,
pretreatment, weekly during completion of therapy, posttreatment, and 3- and 6-month follow-up. Participants are randomized in groups of 8–10
to complete either behavioral activation or exposure-based therapy and are blinded to which intervention they will receive until after completion
of all pretreatment assessments. Tx treatment, BDI-II SI Beck Depression Inventory suicidal ideation item, GAD-7 Generalized Anxiety Disorder 7-
item scale, PROMIS Anx & Dep Patient-Reported Outcomes Measurement Information System anxiety and depression scales, BADS-SF Behavioral
Activation for Depression Scale–Short Form, SDS Sheehan Disability Scale, HRS Homework Rating Scale, OASIS Overall Anxiety Severity and
Impairment Scale, PSWQ Penn State Worry Questionnaire, LSAS Liebowitz Social Anxiety Scale, PDSS Panic Disorder Severity Scale, WAI Working
Alliance Inventory, CEQ Credibility/Expectancy Questionnaire
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events can reduce one’s ability to experience reward or
reinforcement (e.g., reduced social support). Depression
develops and is maintained when individuals respond in
ways that create additional deficits in reward or
reinforcement (e.g., further isolation). The goal of BA is
to identify alternative behaviors to increase in a way that
increases opportunities for reward or reinforcement,
particularly through naturally reinforcing behaviors (e.g.,
those related to one’s values). A ten-session, structured,
group-based BA manual was developed by coauthors
RLA and CM (with edits and revisions provided by AC),
informed by previously published BA treatment guides
[29] and modified to focus on negative mood more gen-
erally rather than solely on depression.
EXP
EXP is a recognized efficacious strategy for the treatment of
anxiety disorders. EXP is based on the premise that anxiety
arises from a perceived threat associated with discrete cues
or contexts, whether from direct or indirect/vicarious ex-
perience or informational transmission of perceived threat.
Anxiety is thought to be maintained by avoidance behavior,
preventing corrective learning. EXP guides individuals to
decrease avoidance and experience anxiety-provoking situa-
tions or cues in a safe environment, allowing for inhibitory
learning or habituation. The ten-session, structured, group-
based EXP manual was based on a previous group-based
anxiety treatment manual [37] developed by MGC, modi-
fied further by MGC and RLA (with edits and revisions
provided by KWT and AC), to focus on exposure strategies
only (without cognitive restructuring) and inhibitory learn-
ing rather than habituation only [38].
Therapist training and treatment fidelity
Each EXP and BA group intervention is delivered by two
cotherapists: a licensed doctoral- or master’s-level clinician
with either another licensed clinician or a therapist in
training (i.e., clinical psychology postdoctoral fellow or
graduate student). Each therapist completes in-person or
online workshops (e.g., Behavioral Tech, LLC, https://
behavioraltech.org; Centre for Research on Eating Disor-
ders at Oxford, https://credo-oxford.com), reads articles
and manuals related to each treatment [29, 38], and
watches videos of previous therapy sessions. Each therapy
session is video and audio recorded, and at least 20% of
sessions will be randomly selected for fidelity ratings. Skill
acquisition and fidelity are assessed using the Quality of
Behavioral Activation Scale for BA (Dimidjian, Hubley,
Martell, Herman-Dunn, and Dobson, 2012, unpublished
measure) and a fidelity form created for the EXP treatment
by RLA in consultation with MGC and KWT. Fidelity rat-
ings will be provided by experts in each therapy (KWT and
CM) or their trainees. Each therapist attends weekly con-
sultation and supervision with the PI and/or consultants.
Data collection
All interview-based assessments (e.g., MINI) are adminis-
tered by experienced, blinded examiners trained to high
levels of interrater reliability (kappa > 0.80). Self-report
data are collected electronically using Research Electronic
Data Capture (REDCap) [39]. Study consent records are
stored in a locked records room at LIBR. Study data re-
cords and blood/urine/biological samples are assigned
code numbers and are not individually identifiable. RED-
Cap servers are housed in a local data center at LIBR, and
all web-based information transmission is encrypted.
Measures
Self-report, behavioral, and neuroimaging measures in-
cluded in the protocol are listed in Table 2 (refer to Fig. 2
for timing of measures). Below are descriptions of the
behavioral and neuroimaging tasks serving as primary
predictors of interest. The remaining tasks are described
in Additional file 1.
AAT
The AAT assesses behavioral avoidance tendencies [71].
Participants are shown a picture of an emotional face
(happy, angry, or neutral) framed by a blue or yellow
border and instructed to pull a joystick (approach) when
the border is one color and to push it away (avoid) when
it is the other (counterbalanced). The picture zooms out
and in accordingly. Mean response latency for push is
subtracted from pull (e.g., angry pull − angry push) to
obtain an avoidance bias score.
AAC task
The AAC task probes decision-making processes during
approach-avoidance conflict [23, 24] (Fig. 3). On each
trial, the subject decides between two outcomes, which
are represented on each side of a runway. A cloud indi-
cates that a negative affective image/sound pair will be
shown, and a sun indicates that a positive image/sound
pair will be shown (e.g., from International Affective Pic-
ture System and International Affective Digitized Sounds
System [72, 73]). The amount of red in a rectangle indi-
cates the amount of money awarded for each option (2, 4,
or 6 cents). For conflict trials, negative stimuli are paired
with rewards. Thus, the same behavior leads to both
affective punishment and reward. For nonconflict “ap-
proach” trials, both outcomes include positive affective
stimuli, but only one offers a reward. For “avoid” trials,
neither outcome offers a reward, but one involves a nega-
tive affective image. For each trial, the subject moves the
avatar, knowing that the probability of each outcome (10–
90%) depends on their end position. Behavioral variables
include approach behavior (end avatar position) and
response time (RT) for initial button press.
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Table 2 Diagnostic, demographic, self-report, behavioral, and
neuroimaging assessments
Diagnostic and demographic assessment
Diagnosis MINI 6.0 or 7.0 [40]
History Assessment of medical and medication history
Treatment completion Intent to complete treatment form
History Tulsa Life chart interview (see Additional file 1)
Standard self-report scales
Negative valence Symptoms of Depression Questionnaire
(SDQ) [41]
Negative valence Overall Anxiety Severity and Impairment
Scale (OASIS) [35]
Negative valence State-Trait Anxiety Inventory (STAI) [42]
Negative valence Anxiety Sensitive Index (ASI-3) [43]
Negative valence Generalized Anxiety Disorder–7 item
(GAD-7) [44]
Negative valence Intolerance of Uncertainty Scale (IUS) [45]
Negative valence Penn State Worry Questionnaire [33]
Negative valence Liebowitz Social Anxiety Scale (LSAS) [46]
Negative valence Panic Disorder Severity Scale (PDSS) [47]
Negative valence Beck Depression Inventory-II (BDI-II) [32]
Negative valence Patient Health Questionnaire-9 [48]
Negative valence Behavioral Activation for Depression
Scale (BADS) [49]
Substance use Customary Drinking and Drug Use Record
(CDDR) [50]
Trauma Traumatic Events Questionnaire (TEQ) [51]
Trauma Child Trauma Questionnaire (CTQ) [52]
Positive/negative
valence
Positive and Negative Affect Schedule
(PANAS) [53]
Positive/negative
valence
Behavioral Inhibition System/Behavioral
Approach Scale (BIS/BAS) [54]
Comorbid anxiety
symptoms
Padua Inventory of Obsessive-Compulsive
Symptoms (PI) [55]
Personality Big Five Inventory (BFI) [56]
Arousal/interoception Multidimensional Assessment of Interoceptive
Awareness (MAIA) [57]
Sleep Pittsburgh Sleep Quality Index (PSQI) [58]
Physical activity International Physical Activity Questionnaire
(IPAQ) [59]
Disability Sheehan Disability Scale (SDS) [30]
Therapy expectancies Credibility/Expectancy Questionnaire
(CEQ) [60]
Therapy compliance Homework Rating Scale (HRS) [61]
Therapy process Working Alliance Inventory (WAI) [62]
Therapy dropout Withdrawn Questionnaire (see Additional file 1)
Pre/post
neuroimaging
Karolinska Sleepiness Scale: prescan (KSS) [63]
Pre/post
neuroimaging
Positive and Negative Affect Schedule:
prescan (PANAS) [53]
NIH PROMIS® [64] and Toolbox® [65] measures
Table 2 Diagnostic, demographic, self-report, behavioral, and
neuroimaging assessments (Continued)
Negative valence PROMIS Anxiety
Negative valence PROMIS Depression
Sleep PROMIS Sleep Disturbance
Sleep PROMIS Sleep-Related Impairment
Social PROMIS Emotional Support
Social PROMIS Information Support
Social PROMIS Instrumental Support
Social PROMIS Social Isolation
Sex PROMIS Global Satisfaction with Sex Life
Sex PROMIS Interest in Sex Activity
Nicotine Nicotine dependence
Negative affect-anger NIH Toolbox Anger-Affect Survey
Negative affect-anger NIH Toolbox Anger-Hostility Survey
Negative affect-anger NIH Toolbox Anger-Physical Aggression Survey
Negative affect-fear NIH Toolbox Fear-Affect Survey
Negative affect-fear NIH Toolbox Fear-Somatic Arousal Survey
Psychological well-
being
NIH Toolbox General Life Satisfaction Survey
Psychological well-
being
NIH Toolbox Meaning and Purpose Survey
Psychological well-
being
NIH Toolbox Positive Affect Survey
Social NIH Toolbox Friendship Survey
Social NIH Toolbox Loneliness Survey
Stress and self-efficacy NIH Toolbox Perceived Stress Survey
Stress and self-efficacy NIH Toolbox Self-Efficacy Survey
Behavioral and neuroimaging tasks (see Additional file 1 for further
description)
Approach/avoidance Implicit approach/avoidance task
Approach/avoidance Attentional bias/dot probe task [66]
Approach/avoidance Signal detection reinforcement task
Approach/avoidance Human behavioral pattern monitor (hBPM)
Estimated IQ Wide Range Achievement Test (WRAT) [67]
Neuropsychological Delis-Kaplan Executive Function System (DKEFS)
color-word test [68]
Neuropsychological DKEFS verbal fluency [68]
Neuropsychological Wechsler Adult Intelligence Scale (WAIS-IV) digit
span [69]
Neuropsychological WAIS-IV digit symbol coding [69]
Neuropsychological Finger Tapping Test
Neuropsychological California Verbal Learning Test (CVLT) [70]
Neuroimaging MRI anatomical scan (T1-weighted)
Neuroimaging fMRI resting state with eyes open
Neuroimaging Approach-avoidance conflict (AAC) task
Neuroimaging Emotional faces task (EFT)
Neuroimaging Monetary incentive delay (MID) task
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During behavioral tasks, the BioPac MP150 system
and AcqKnowledge software (BIOPAC Systems, Inc.,
Goleta, CA, USA) are used to collect galvanic skin con-
ductance, heart rate (electrocardiogram), and respiration
rate (respiration transducer). MRI data are collected on
a GE MR750 3.0T MRI scanner (GE Healthcare Life Sci-
ences, Chicago, IL, USA). Analysis of Functional NeuroI-
mages [74] is used for processing of MRI data.
Electroencephalography (EEG) is simultaneously per-
formed during MRI scanning using a 31-electrode cap
attached to an MRI-compatible BrainAmp MR Plus
amplifier (Brain Products GmbH, Gilching, Germany).
Blood samples for plasma, serum, and peripheral blood
mononuclear cells are collected at baseline and post-
treatment to quantify biomarkers for future exploratory
analyses. See Additional file 1 for further description of
MRI, EEG, and blood biomarker methods.
Analysis procedures
The characteristics of all measures will be examined for
missing data and deviation from normality prior to sub-
sequent analyses. Baseline demographic characteristics
and attrition data will be contrasted between treatment
groups, and analyses will be adjusted to account for
potential confounders. For the first aim, we will test the
hypotheses that approach and conflict arbitration behav-
ior, and neural responses will explain significant variance
in baseline symptoms above and beyond avoidance-
related behavior and neural responses. Approach and
avoidance behavior are defined by AAT bias scores; con-
flict arbitration is defined by RT during AAC conflict tri-
als. For brain responses, we will focus on the AAC task
and extracted percentage signal change from the follow-
ing a priori regions of interest:
1. Approach: left caudate (reward versus no-reward
outcome)
2. Avoidance: right amygdala (negative versus positive
affective outcome)
3. Conflict: right dlPFC (conflict versus nonconflict
decisions)
We will use Huber robust regression with baseline
GAD-7 as the dependent variable (DV) and approach,
avoidance, and conflict measures as independent vari-
ables (IVs).
For the second aim, we will test the hypotheses that
approach-related and conflict arbitration behavior and
Fig. 3 Approach-avoidance conflict (AAC) task. This figure displays (1) example decision screens displayed during the task for each of the five
conditions: avoid-threat, approach-reward, and conflict with 2, 4, or 6 cents offered and (2) the sequence of screens presented for each AAC trial,
including a decision phase followed by presentation of the affective image and sound pair (e.g., from International Affective Picture System and
International Affective Digitized Sounds system [72, 73]), display of the number of cents received, and then a fixation cross until the next
trial begins
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neural responses will predict treatment response above
and beyond avoidance-related behavior and neural re-
sponses. We will use linear mixed models (LMEs) with
random subject-level intercepts and slopes, GAD-7
scores across the ten sessions as DVs; baseline GAD-7
as a covariate; and approach, avoidance, and conflict
measures as IVs. The main effect of intervention type
and its interaction with IVs will be included to deter-
mine treatment main effects and moderating effects. We
will determine the best set of IVs using the Lasso
method [75], and we will use functional linear models
[76] to model on-parametric symptom trajectories as
needed.
For the third aim, we will test the hypothesis that the
degree to which conflict arbitration abilities increase
with treatment will positively relate to functional im-
provement from pre- to posttreatment. We will use
LMEs to test main and interaction effects between inter-
vention type and change in AAC conflict arbitration in
predicting trajectories of GAD-7 scores over the ten ses-
sions. We will employ the asymmetric distribution of
product of coefficients test (versus Baron and Kenny
methods) due to the greater power and more appropri-
ate type I error rate it affords [77].
In addition, we are collecting data from other mea-
sures for exploratory analyses. For such analyses, we will
explore (1) data reduction methods to derive multilevel
factors associated with approach, avoidance, and conflict
arbitration processes; and (2) use of random forest ma-
chine learning, which is particularly appropriate with a
large ratio of predictors to participants [78], to identify
predictors of treatment outcome.
Sample size and power analysis
Previous research suggests large effects for fMRI predic-
tors (i.e., r = 0.60–0.75) and medium to large effects for
behavioral predictors (r = 0.30–0.47) of intervention out-
comes [79, 80]. For this study, we aim to recruit 100 par-
ticipants, which with 20% attrition would allow for
complete longitudinal data for 80 participants (i.e., ~ 40/
intervention). LMEs will include all participants with any
postbaseline assessments. Thus, we anticipate approxi-
mately 50 participants per intervention for aims 2/3. For
relationships between individual predictors and DVs, we
estimate having 80% power to detect medium to large ef-
fects (r = 0.27 for N = 100; r = 0.37 for N = 50; α = 0.05). In
a model with three predictors (approach, avoidance, con-
flict arbitration), we also estimate having 80% power to
detect medium to large effects (η2 = 0.11 for N = 100; η2 =
0.24 for N = 50).
Design considerations
We considered an alternative design where we examined
predictors of EXP response compared with an attentional
control intervention. We instead decided to identify
unique predictors of two theoretically divergent behavioral
therapies because (1) the current protocol was not meant
to test intervention efficacy compared with “placebo” (be-
cause efficacy has been established in previous research);
(2) variability in outcomes would be greatest for effica-
cious, as opposed to placebo, interventions, thus enhan-
cing statistical power for prediction; and (3) identifying
unique predictors for two therapies would be most clinic-
ally meaningful. We also considered using more unified
cognitive behavioral interventions [81]. However, inter-
ventions that simultaneously target multiple processes
(e.g., both cognitive and behavioral strategies) would have
made it more difficult to identify predictors relating to the
specific therapeutic target. The goal here is to foster indi-
vidualized, precision targeting of treatments rather than to
apply more broadly targeted treatments to all patients.
Ethics
Study approval was obtained from the Western Institu-
tional Review Board (WIRB) (protocol 20151232)
Additional file 3. Any protocol modifications will be made
to records at ClinicalTrials.gov and communicated to study
investigators, WIRB, and funding organizations as required.
Gender/minority/pediatric inclusion for research
Planned study enrollment is reflective of Tulsa County
population demographics and is described further in Add-
itional file 1. We will not exclude subjects based on sex,
gender, race, or ethnicity. Children are not included, owing
to our initial focus on understanding neurobehavioral pre-
dictors of exposure therapy for adults with GAD. The vari-
ability introduced by developmental changes could reduce
sensitivity to detect hypothesized relationships.
Safety
The risk for adverse events is minimal. The study is a
clinical trial but is not a phase III trial, involves only one
site, is not blinded, and does not employ high-risk inter-
ventions or vulnerable populations. The interventions
employed are known to be efficacious for the treatment
of anxiety or depression. The PI (RLA), in collaboration
with mentor and LIBR scientific director (MPP), are per-
forming the monitoring function for the study. Any un-
anticipated adverse events will be reported immediately
to the LIBR Human Protection Administrator and to the
Western IRB. Any adverse events will be included in the
annual IRB report.
Each week prior to session, participants complete ques-
tionnaires assessing symptom severity and suicidal idea-
tion. As needed, a therapist meets with the participant
individually to assess risk and provide referrals or identify
emergency services. LIBR is situated on a campus with an
inpatient psychiatric hospital (Laureate Psychiatric Clinic
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and Hospital), which has a 24-h clinical assessment
department.
Dissemination
Results will be shared with the scientific and health profes-
sional community through presentation at national and
international scientific meetings and publication in scien-
tific journals. The full protocol and statistical code used
for data analysis will be provided with resulting publica-
tions. To disseminate results to the general public, all final
peer-reviewed manuscripts will be submitted to the
PubMed Central digital archive in compliance with the
NIH public access policy. The PI will maintain a local
website where lay summaries of scientific results will be
provided, with appropriate links to scientific presentations
and publications. The PI will ensure that the summary of
results information is submitted to ClinicalTrials.gov.
Discussion
To enhance treatment effectiveness and efficiency for in-
dividuals with anxiety and depression, it will be benefi-
cial to understand why many patients do not respond
optimally to gold standard therapies and to be able to
predict, before treatment begins which patients will re-
spond to which treatments. The study detailed in this
protocol article represents a first step toward these goals,
using the RDoC framework [12] to probe multilevel pre-
dictors of EXP versus BA therapy for GAD. This work
addresses the NIMH strategic plan by (1) integrating
biological markers and behavioral indicators associated
with GAD (strategy 1.3) and (2) using a multidimen-
sional design to ascertain individual predictors of ther-
apy response (strategy 3.1) that will (3) inform future
research developing strategies for personalized mental
health care (strategy 3.2).
Czajkowski et al. [82] presented the Obesity-Related
Behavioral Intervention Trials (ORBIT) model as a strat-
egy for the development of novel behavioral treatments.
Although the ORBIT model was developed from a
health psychology perspective, it is also relevant more
broadly. These authors proposed that “the hypothesis
that change in a behavioral risk factor could solve a clin-
ical problem is one of the entry points for behavioral
treatment development” [82]. Similarly, the identification
of neural and behavioral risk factors for response or
nonresponse to different psychosocial treatments could
provide entry points for development of novel, personal-
ized mental health treatment strategies. If specific behav-
iors (i.e., conflict arbitration difficulties, approach
motivation) and/or neural networks (e.g., dlPFC, stri-
atum) can be shown to predict therapy outcomes, re-
search could then turn toward identifying strategies for
modifying these factors. This could involve neuromodu-
lation approaches (e.g., fMRI real-time neurofeedback,
transcranial magnetic stimulation) [83], cognitive or be-
havioral strategies (e.g., cognitive control or attention
bias training, cognitive rehabilitation strategies [84, 85]),
or pharmacologic approaches (e.g., dopaminergic or N-
methyl-D-aspartate-related drugs to target motivational
or cognitive circuitry, respectively) [86]. This approach is
in concert with NIMH’s more recent experimental
therapeutic approach to clinical trials.
Strengths of the described protocol include the
randomization of participants to two interventions, both of
which have documented efficacy but target different and
specific processes rooted in distinct neural circuitry. The
study is strengthened by inclusion of multilevel assess-
ments—self-report, behavioral, and neurobiological—to
probe domains of positive and negative valence and cogni-
tive control. In addition, the domains and interventions
assessed are relevant transdiagnostically. Thus, if promising
results are identified, future studies could use similar proto-
cols to test whether findings can be generalized to other
anxiety disorder and depressive disorder populations. In
addition, the interventions are manualized and identical in
regard to format, frequency, duration, and level of therapist
training, and we use consultation with experts in each.
The study is not without limitations. Although our tar-
get sample size is larger than any published fMRI study
predicting GAD treatment response, the sample size is
underpowered to detect small effect sizes or for inde-
pendent replications. Thus, results identified from the
current study will require follow-up replication. Also,
the trial is being conducted at only one site, so
generalizability across sites would need to be determined
in future research. The delivery of the intervention in a
group format allows for greater control and balance re-
garding which therapists are providing the treatment,
and it increases cost and time efficiency of the trial.
However, this may limit the generalizability of findings
to individual therapy.
This protocol provides a framework for how studies may
be designed to move the field toward neuroscience-
informed and personalized psychosocial treatments. The re-
sults of the trial will have implications for approach-
avoidance processing in GAD; relationships between levels
of analysis (i.e., behavioral, neural); and, most important,
predictors of behavioral therapy outcome. The results also
have the potential to inform a line of research aimed at op-
timizing psychosocial treatment for anxiety and depressive
disorders from a holistic, neuroscience, and behaviorally in-
formed perspective and to move us closer to truly personal-
ized precision approaches to psychiatric treatment.
Trial status
Study approval was obtained from the Western Institu-
tional Review Board (WIRB; protocol 20151232). Re-
cruitment began on June 7, 2016, and the approximate
Santiago et al. Trials           (2020) 21:17 Page 11 of 14
date when recruitment will be completed is April 1,
2021. The study was retrospectively registered within 21
days of first participant enrollment in accordance with
FDAAA 801 (ClinicalTrials.gov identifier NCT02807480;
registration date June 21, 2016).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3802-9.
Additional file 1. Supplementary material: Additional information on
methods and analysis of the interventions, assessments (behavioral and
neuroimaging), blood biomarker storage, and plans for enrollment.
Additional file 2. SPIRIT checklist: Information regarding the
recommended items for a clinical trial protocol paper.
Additional file 3. Approval letter from Western Institutional Review
Board.
Additional file 4. K23 Notice of Award: Letter from the National
Institute of Mental Health informing the principal investigator of the
award granted for this protocol.
Additional file 5. Study consent form: The informed consent document
approved by the Western Institutional Review Board.
Abbreviations
AAC: Approach-avoidance conflict; AAT: Approach-Avoidance Task;
ABC: Antecedent, behavior, and consequence; ACTION: Assess behavior/
mood, choose alternate responses, try out alternate responses, integrate
these alternatives, observe results, now evaluate; BA: Behavioral activation;
BADS-SF: Behavioral Activation for Depression Scale–Short Form; BDI-II: Beck
Depression Inventory II; BDI-II SI: Beck Depression Inventory suicidal ideation
item; CBT: Cognitive behavioral therapy; CEQ: Credibility/Expectancy
Questionnaire; dlPFC: Dorsolateral prefrontal cortex; DSM-5: Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition; DV: Dependent variable;
EEG: Electroencephalography; EXP: Exposure therapy; fMRI: Functional
magnetic resonance imaging; GAD: Generalized anxiety disorder; GAD-
7: Generalized Anxiety Disorder 7-item scale; HRS: Homework Rating Scale;
IV: Independent variable; LIBR: Laureate Institute for Brain Research;
LME: Linear mixed models; LSAS: Liebowitz Social Anxiety Scale; MDD: Major
depressive disorder; MINI: Mini International Neuropsychiatric Interview;
MRI: Magnetic resonance imaging; NIH: National Institutes of Health;
NIMH: National Institute of Mental Health; OASIS: Overall Anxiety Severity and
Impairment Scale; ORBIT: Obesity-Related Behavioral Intervention Trials;
PDSS: Panic Disorder Severity Scale; PFC: Prefrontal cortex; PROMIS Anx &
Dep: Patient-Reported Outcomes Measurement Information System anxiety
and depression scales; PSC: Percentage signal change; PSWQ: Penn State
Worry Questionnaire; RDoC: Research Domain Criteria; REDCap: Research
Electronic Data Capture; RT: Response time; SDS: Sheehan Disability Scale;
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials;
SSRI: Selective serotonin reuptake inhibitor; TRAC: trigger, response,
alternative coping; TRAP: trigger, response, avoidance pattern; Tx: treatment;
WAI: Working Alliance Inventory; WIRB: Western Institutional Review Board
Acknowledgements
We acknowledge the support and work of graduate students and
postdoctoral fellows who have or will contribute to the delivery of the
interventions described in this protocol. In addition, we acknowledge
Catherine Ayers, PhD, for providing the group-based anxiety treatment man-
ual used in her previous work to inform the exposure-based manual used in
the current protocol. Last, we also acknowledge the participants who have
or will in the future volunteer their time to this study.
Authors’ contributions
JS contributed to data collection, literature search, intervention delivery,
creation of figures/tables, and initial drafting and revision of the manuscript.
EA contributed to data collection, literature search, creation of figures/tables,
and revision of the manuscript. NK contributed to literature search,
intervention delivery, and revision of the manuscript. ANC contributed to
study design, data collection, intervention delivery, revision of intervention
manuals, and revision of the manuscript. KTC contributed to data collection,
literature search, and revision of the manuscript. TJM contributed to data
collection, literature search, and revision of the manuscript. BM contributed
to data collection, literature search, creation of figures/tables, and revision of
the manuscript. MPM contributed to study design, analytic plan, and revision
of the manuscript. MGC contributed to study design, analytic plan, exposure
therapy manual development, and revision of the manuscript. JB contributed
to study design, analytic plan, and revision of the manuscript. JA contributed
to study design, analytic plan, and revision of the manuscript. CM
contributed to behavioral activation manual development, consultation on
intervention delivery, and revision of the manuscript. KWT provided revision
of the exposure therapy manual, consultation on intervention delivery, and
revision of the manuscript. WKT contributed to the analytic plan and revision
of the manuscript. RLA contributed to study design, data collection,
intervention manual development and delivery, supervision of intervention
delivery, data analysis, literature search, creation of figures/tables, and initial
drafting and revision of the manuscript. All authors read and approved the
final manuscript.
Funding
This work was supported by National Institute of Mental Health grant
K23MH108707 (Robin L. Aupperle, PhD, principal investigator) and the
William K. Warren Foundation (Additional file 4). The study sponsor and
funding organizations will have no direct role in data collection, analysis, or
interpretation; trial design; patient recruitment; or any aspect pertinent to
the study. The authors were not paid to write this article by a
pharmaceutical company or other agency. The authors will have full access
to all the data in the study and have final responsibility for the decision to
submit it for publication.
Availability of data and materials
The datasets analyzed during the current study are available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
Study approval was obtained under WIRB protocol 20151232. Informed
consent will be obtained from all study participants. Any protocol
modifications will be made to records on ClinicalTrials.gov and
communicated to study investigators, WIRB, and funding organizations as
required.
Consent for publication
Not applicable. Individually identifiable data is not included in this
manuscript.
Competing interests
Jessica Santiago, Elisabeth Akeman, Kelly Cosgrove, Bailey Mathis, Timothy
McDermott, and Drs. James Abelson and Wes Thompson have no conflicts
of interest to declare. Drs. Namik Kirlic and Jerzy Bodurka report receiving
grants from the National Institute for General Medical Sciences. Dr. Ashley
Clausen is funded by the Department of Veterans Affairs Office of Academic
Affiliations Advanced Fellowship Program in Mental Illness Research and
Treatment; the Medical Research Service of the Durham VA Health Care
System; and the Department of Veterans Affairs Mid-Atlantic Mental Illness
Research, Education, and Clinical Center (MIRECC). Dr. Michelle Craske reports
receiving grants from the National Institute of Mental Health. Dr. Christopher
Martell reports receiving royalties for four books on the topic of behavioral
activation. Dr. Kathryn Wolitzky-Taylor reports receiving grants from the Na-
tional Institute on Alcohol Abuse and Alcoholism and the National Institute
on Drug Abuse. Dr. Martin Paulus has received royalties for an article about
methamphetamine published in UpToDate and grants from the National In-
stitute of General Medical Sciences and the National Institute of Mental
Health. Dr. Robin Aupperle reports receiving grants from the National Insti-
tute of Mental Health, the National Institute of General Medical Sciences, and
Oklahoma Science and Technology Research and Development. The views
expressed in this article are those of the authors and do not necessarily re-
flect the position or policy of the Department of Veterans Affairs or the U.S.
government.
Santiago et al. Trials           (2020) 21:17 Page 12 of 14
Author details
1Laureate Institute for Brain Research, 6655 South Yale Avenue, Tulsa, OK
74136, USA. 2School of Community Medicine, University of Tulsa, Tulsa, OK,
USA. 3Department of Psychology, University of Tulsa, Tulsa, OK, USA. 4VA
Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham,
NC, USA. 5Duke University Brain Imaging and Analysis Center, Durham, NC,
USA. 6Psychology, Psychiatry and Biobehavioral Sciences, University of
California, Los Angeles, Los Angeles, CA, USA. 7Department of Psychiatry,
University of Michigan, Ann Arbor, MI, USA. 8Department of Psychological
and Brain Sciences, University of Massachusetts–Amherst, Amherst, MA, USA.
9Stephenson School of Biomedical Engineering, The University of Oklahoma,
Norman, OK, USA. 10Family Medicine and Public Health, University of
California, San Diego, San Diego, CA, USA.
Received: 13 August 2019 Accepted: 11 October 2019
References
1. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35(1):1–
14. https://doi.org/10.1016/j.psc.2011.11.005.
2. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to
society. Depress Anxiety. 2002;16(4):162–71. https://doi.org/10.1002/da.10065.
3. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of
generalized anxiety disorder. Depress Anxiety. 2008;25(1):72–90. https://doi.
org/10.1002/da.20257.
4. Penninx BW, Nolen WA, Lamers F, Zitman FG, Smit JH, Spinhoven P, et al.
Two-year course of depressive and anxiety disorders: results from the
Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord.
2011;133(1–2):76–85. https://doi.org/10.1016/j.jad.2011.03.027.
5. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM, et al.
Depression and generalized anxiety disorder: cumulative and sequential
comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen
Psychiatry. 2007;64(6):651–60. https://doi.org/10.1001/archpsyc.64.6.651.
6. Sherbourne CD, Wells KB. Course of depression in patients with comorbid
anxiety disorders. J Affect Disord. 1997;43(3):245–50. https://doi.org/10.1016/
s0165-0327(97)01442-0.
7. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic
treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):
864–72. https://doi.org/10.1177/0269881107076996.
8. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety
disorders: a meta-analysis of randomized placebo-controlled trials. J Clin
Psychiatry. 2008;69(4):621–32. https://doi.org/10.4088/jcp.v69n0415.
9. Hollon SD, Stewart MO, Strunk D. Enduring effects for cognitive behavior
therapy in the treatment of depression and anxiety. Annu Rev Psychol.
2006;57:285–315. https://doi.org/10.1146/annurev.psych.57.102904.190044.
10. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G.
Psychological treatment of generalized anxiety disorder: a meta-analysis.
Clin Psychol Rev. 2014;34(2):130–40. https://doi.org/10.1016/j.cpr.2014.01.002.
11. Marciniak MD, Lage MJ, Dunayevich E, Russell JM, Bowman L, Landbloom RP,
et al. The cost of treating anxiety: the medical and demographic correlates
that impact total medical costs. Depress Anxiety. 2005;21(4):178–84.
12. Sanislow CA, Pine DS, Quinn KJ, Kozak MJ, Garvey MA, Heinssen RK, et al.
Developing constructs for psychopathology research: research domain criteria.
J Abnorm Psychol. 2010;119(4):631–9. https://doi.org/10.1037/a0020909.
13. Craske MG. Honoring the past, envisioning the future: ABCT’s 50th
anniversary presidential address. Behav Ther. 2018;49(2):151–64. https://doi.
org/10.1016/j.beth.2017.05.003.
14. Fernandes BS, Williams LM, Steiner J, Leboyer M, Carvalho AF, Berk M. The
new field of ‘precision psychiatry’. BMC Med. 2017;15:80.
15. Altamura AC, Dell’osso B, D’Urso N, Russo M, Fumagalli S, Mundo E. Duration of
untreated illness as a predictor of treatment response and clinical course in
generalized anxiety disorder. CNS Spectr. 2008;13(5):415–22.
16. Blair KS, Blair R. A cognitive neuroscience approach to generalized anxiety
disorder and social phobia. Emot Rev. 2012;4(2):133–8. https://doi.org/10.
1177/1754073911430251.
17. Santos VA, Carvalho DD, Van Ameringen M, Nardi AE, Freire RC.
Neuroimaging findings as predictors of treatment outcome of
psychotherapy in anxiety disorders. Prog Neuropsychopharmacol Biol
Psychiatry. 2019;91:60–71. https://doi.org/10.1016/j.pnpbp.2018.04.001.
18. Ball TM, Stein MB, Ramsawh HJ, Campbell-Sills L, Paulus MP. Single-subject
anxiety treatment outcome prediction using functional neuroimaging.
Neuropsychopharmacology. 2014;39(5):1254–61. https://doi.org/10.1038/
npp.2013.328.
19. Behar E, DiMarco ID, Hekler EB, Mohlman J, Staples AM. Current theoretical
models of generalized anxiety disorder (GAD): conceptual review and
treatment implications. J Anxiety Disord. 2009;23(8):1011–23. https://doi.org/
10.1016/j.janxdis.2009.07.006.
20. Aupperle RL, Paulus MP. Neural systems underlying approach and
avoidance in anxiety disorders. Dialogues Clin Neurosci. 2010;12(4):517–31.
21. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol.
2003;70(2):83–244.
22. Kirlic N, Young J, Aupperle RL. Animal to human translational paradigms
relevant for approach avoidance conflict decision making. Behav Res Ther.
2017;96:14–29. https://doi.org/10.1016/j.brat.2017.04.010.
23. Aupperle RL, Melrose AJ, Francisco A, Paulus MP, Stein MB. Neural substrates
of approach-avoidance conflict decision-making. Hum Brain Mapp. 2015;
36(2):449–62. https://doi.org/10.1002/hbm.22639.
24. Aupperle RL, Sullivan S, Melrose AJ, Paulus MP, Stein MB. A reverse translational
approach to quantify approach-avoidance conflict in humans. Behav Brain Res.
2011;225(2):455–63. https://doi.org/10.1016/j.bbr.2011.08.003.
25. Craske MG, Barlow DH. Mastery of your anxiety and worry. 2nd ed. San
Antonio: Psychological Corp.; 2006.
26. Dillon DG, Rosso IM, Pechtel P, Killgore WD, Rauch SL, Pizzagalli DA. Peril
and pleasure: an RDOC-inspired examination of threat responses and
reward processing in anxiety and depression. Depress Anxiety. 2014;31(3):
233–49. https://doi.org/10.1002/da.22202.
27. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of
depression: a meta-analysis. Clin Psychol Rev. 2007;27(3):318–26. https://doi.
org/10.1016/j.cpr.2006.11.001.
28. Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, Bystritsky A.
Treatment for anxiety disorders: efficacy to effectiveness to implementation.
Behav Res Ther. 2009;47(11):931–7. https://doi.org/10.1016/j.brat.2009.07.012.
29. Martell CR, Dimidjian S, Herman-Dunn R. Behavioral activation for
depression: a clinician’s guide. New York: Guilford Press; 2013.
30. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int
Clin Psychopharmacol. 1996;11 Suppl 3:89–95.
31. Schalet BD, Pilkonis PA, Yu L, Dodds N, Johnston KL, Yount S, et al. Clinical validity
of PROMIS depression, anxiety, and anger across diverse clinical samples. J Clin
Epidemiol. 2016;73:119–27. https://doi.org/10.1016/j.jclinepi.2015.08.036.
32. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression
Inventories-IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):
588–97. https://doi.org/10.1207/s15327752jpa6703_13.
33. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation
of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–95.
https://doi.org/10.1016/0005-7967(90)90135-6.
34. American Psychiatric Association. Diagnostic and statistical manual of mental
disorders (DSM-5®). 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
35. Norman SB, Hami Cissell S, Means-Christensen AJ, Stein MB. Development
and validation of an overall anxiety severity and impairment scale (OASIS).
Depress Anxiety. 2006;23(4):245–9.
36. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al.
Randomized trial of behavioral activation, cognitive therapy, and antidepressant
medication in the acute treatment of adults with major depression. J Consult Clin
Psychol. 2006;74(4):658–70. https://doi.org/10.1037/0022-006X.74.4.658.
37. Arch JJ, Ayers CR, Baker A, Almklov E, Dean DJ, Craske MG. Randomized
clinical trial of adapted mindfulness-based stress reduction versus group
cognitive behavioral therapy for heterogeneous anxiety disorders. Behav
Res Ther. 2013;51(4–5):185–96. https://doi.org/10.1016/j.brat.2013.01.003.
38. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing
exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:
10–23. https://doi.org/10.1016/j.brat.2014.04.006.
39. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
Electronic Data Capture (REDCap) – a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010.
40. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The
Mini-International Neuropsychiatric Interview (M.I.N.I.): development and
validation of a structured diagnostic psychiatric interview. J Clin Psychiatry. 1998;
59 Suppl 20:22–33.
41. Pedrelli P, Blais MA, Alpert JE, Shelton RC, Walker RS, Fava M. Reliability and
validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectr.
2014;19(6):535–46. https://doi.org/10.1017/S1092852914000406.
Santiago et al. Trials           (2020) 21:17 Page 13 of 14
42. Spielberger C. State-Trait Anxiety Inventory (Form Y) manual. Palo Alto:
Mind Garden; 1983.
43. Taylor S, Koch WJ, McNally RJ, Crockett DJ. Conceptualizations of anxiety
sensitivity. Psychol Assess. 1992;4(2):245.
44. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):
1092–7. https://doi.org/10.1001/archinte.166.10.1092.
45. Buhr K, Dugas MJ. The intolerance of uncertainty scale: psychometric
properties of the English version. Behav Res Ther. 2002;40(8):931–45. https://
doi.org/10.1016/s0005-7967(01)00092-4.
46. Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The Liebowitz social anxiety
scale as a self-report instrument: a preliminary psychometric analysis. Behav
Res Ther. 2002;40(6):701–15.
47. Shear MK, Rucci P, Williams J, Frank E, Grochocinski V, Vander Bilt J, et al.
Reliability and validity of the Panic Disorder Severity Scale: replication and
extension. J Psychiatr Res. 2001;35(5):293–6. https://doi.org/10.1016/s0022-
3956(01)00028-0.
48. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16(9):606–13. https://doi.org/10.
1046/j.1525-1497.2001.016009606.x.
49. Kanter JW, Mulick PS, Busch AM, Berlin KS, Martell CR. The Behavioral
Activation for Depression Scale (BADS): psychometric properties and factor
structure. J Psychopathol Behav. 2007;29(3):191. https://doi.org/10.1007/
s10862-006-9038-5.
50. Brown SA, Myers MG, Lippke L, Tapert SF, Stewart DG, Vik PW. Psychometric
evaluation of the Customary Drinking and Drug Use Record (CDDR): a
measure of adolescent alcohol and drug involvement. J Stud Alcohol. 1998;
59(4):427–38. https://doi.org/10.15288/jsa.1998.59.427.
51. Vrana S, Lauterbach D. Prevalence of traumatic events and post-traumatic
psychological symptoms in a nonclinical sample of college students. J
Trauma Stress. 1994;7(2):289–302.
52. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial
reliability and validity of a new retrospective measure of child abuse and neglect.
Am J Psychiatry. 1994;151(8):1132. https://doi.org/10.1176/ajp.151.8.1132.
53. Watson D, Clark LA, Tellegen A. Development and validation of brief
measures of positive and negative affect: the PANAS scales. J Pers Soc
Psychol. 1988;54(6):1063–70. https://doi.org/10.1037//0022-3514.54.6.1063.
54. Carver CS, White TL. Behavioral inhibition, behavioral activation, and
affective responses to impending reward and punishment: the BIS/BAS
scales. J Pers Soc Psychol. 1994;67(2):319.
55. Burns GL, Keortge SG, Formea GM, Sternberger LG. Revision of the Padua
Inventory of obsessive compulsive disorder symptoms: distinctions between
worry, obsessions, and compulsions. Behav Res Ther. 1996;34(2):163–73.
56. John OP, Srivastava S. The Big Five trait taxonomy: history, measurement,
and theoretical perspectives. Handbook of personality: Theory and research.
1999;2(1999):102–38.
57. Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A. The
Multidimensional Assessment of Interoceptive Awareness (MAIA). PLoS One.
2012;7(11):e48230. https://doi.org/10.1371/journal.pone.0048230.
58. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh
Sleep Quality Index. J Psychosom Res. 1998;45(1):5–13. https://doi.org/10.
1016/s0022-3999(97)00298-5.
59. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE,
et al. International Physical Activity Questionnaire: 12-country reliability and
validity. Med Sci Sports Exerc. 2003;35(8):1381–95. https://doi.org/10.1249/01.
MSS.0000078924.61453.FB.
60. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/
expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86.
61. Kazantzis N, Deane FP, Ronan KR. Assessing compliance with homework
assignments: review and recommendations for clinical practice. J Clin
Psychol. 2004;60(6):627–41. https://doi.org/10.1002/jclp.10239.
62. Hatcher RL, Gillaspy JA. Development and validation of a revised short
version of the Working Alliance Inventory. Psychother Res. 2006;16(1):12–25.
https://doi.org/10.1080/10503300500352500.
63. Kaida K, Takahashi M, Åkerstedt T, Nakata A, Otsuka Y, Haratani T, et al.
Validation of the Karolinska Sleepiness Scale against performance and EEG
variables. Clin Neurophysiol. 2006;117(7):1574–81. https://doi.org/10.1016/j.
clinph.2006.03.011.
64. Broderick JE, DeWitt EM, Rothrock N, Crane PK, Forrest CB. Advances in
patient-reported outcomes: the NIH PROMIS® measures. EGEMS. 2013;1(1):
2015. https://doi.org/10.13063/2327-9214.
65. Salsman JM, Butt Z, Pilkonis PA, Cyranowski JM, Zill N, Hendrie HC, et al.
Emotion assessment using the NIH Toolbox. Neurology. 2013;80(11
Supplement 3):S76–86. https://doi.org/10.1212/WNL.0b013e3182872e11.
66. Matsumoto D, Ekman P. Japanese and Caucasian facial expressions of
emotion (JACFEE). San Francisco: Intercultural and Emotion Research
Laboratory, Department of Psychology, San Francisco State University; 1988.
67. Wilkinson GS, Robertson GJ. Wide Range Achievement Test 4 professional
manual. Lutz: Psychological Assessment Resources; 2006.
68. Delis DC, Kaplan E. Delis-Kaplan Executive Function battery. San Antonio:
Psychological Corpor.; 2001.
69. Wechsler D, Coalson DL, Raiford SE. WAIS-IV technical and interpretive
manual. San Antonio: Psychological Corp.; 2008.
70. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test.
Second ed. San Antonio: The Psychological Corp.; 2000.
71. Heuer K, Rinck M, Becker ES. Avoidance of emotional facial expressions in
social anxiety: the approach-avoidance task. Behav Res Ther. 2007;45(12):
2990–3001. https://doi.org/10.1016/j.brat.2007.08.010.
72. Lang PJ, Bradley MM, Cuthbert BN. International Affective Picture System
(IAPS): affective ratings of pictures and instruction manual. Technical Report
A-8. Gainesville: University of Florida; 2008.
73. Bradley MM, Lang PJ. International Affective Digitized Sounds (IADS): stimuli,
instruction manual, and affective ratings. Tech. Rep. No. B-2. Gainesville:
Center for Research in Psychophysiology, University of Florida; 1999.
74. Cox RW. AFNI: software for analysis and visualization of functional magnetic
resonance neuroimages. Comput Biomed Res. 1996;29(3):162–73. https://
doi.org/10.1006/cbmr.1996.0014.
75. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc
Series B Stat Methodol. 1996;58(1):267–88.
76. Ramsay J, Silverman BW. Functional data analysis. New York: Springer
Science + Business; 2005.
77. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A
comparison of methods to test mediation and other intervening variable
effects. Psychol Methods. 2002;7(1):83–104.
78. Bureau A, Dupuis J, Falls K, Lunetta KL, Hayward B, Keith TP, et al. Identifying
SNPs predictive of phenotype using random forests. Genet Epidemiol. 2005;
28(2):171–82.
79. Arch JJ, Ayers CR. Which treatment worked better for whom? Moderators of
group cognitive behavioral therapy versus adapted mindfulness based
stress reduction for anxiety disorders. Behav Res Ther. 2013;51(8):434–42.
https://doi.org/10.1016/j.brat.2013.04.004.
80. Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Davidson RJ,
et al. Anticipatory activation in the amygdala and anterior cingulate in
generalized anxiety disorder and prediction of treatment response. Am J
Psychiatry. 2009;166(3):302–10. https://doi.org/10.1176/appi.ajp.2008.07101682.
81. Farchione TJ, Fairholme CP, Ellard KK, Boisseau CL, Thompson-Hollands J,
Carl JR, et al. Unified protocol for transdiagnostic treatment of emotional
disorders: a randomized controlled trial. Behav Ther. 2012;43(3):666–78.
https://doi.org/10.1016/j.beth.2012.01.001.
82. Czajkowski SM, Powell LH, Adler N, Naar-King S, Reynolds KD, Hunter CM,
et al. From ideas to efficacy: the ORBIT model for developing behavioral
treatments for chronic diseases. Health Psychol. 2015;34(10):971. https://doi.
org/10.1037/hea0000161.
83. Young KD, Zotev V, Phillips R, Misaki M, Drevets WC, Bodurka J. Amygdala
real-time functional magnetic resonance imaging neurofeedback for major
depressive disorder: a review. Psychiatry Clin Neurosci. 2018;72(7):466–81.
https://doi.org/10.1111/pcn.12665.
84. Clausen AN, Thelen J, Francisco AJ, Bruce J, Martin L, McDowd J, et al.
Computer-based executive function training for combat veterans with
PTSD: a pilot clinical trial assessing feasibility and predictors of dropout.
Front Psychiatry. 2019;10:62. https://doi.org/10.3389/fpsyt.2019.00062.
85. Amir N, Beard C, Burns M, Bomyea J. Attention modification program in
individuals with generalized anxiety disorder. J Abnorm Psychol. 2009;
118(1):28–33. https://doi.org/10.1037/a0012589.
86. Choi DC, Rothbaum BO, Gerardi M, Ressler KJ. Pharmacological
enhancement of behavioral therapy: focus on posttraumatic stress disorder.
In: Stein M, Steckler T, editors. Behavioral neurobiology of anxiety and its
treatment. Vol. 2. Berlin: Springer; 2009. p. 279–99.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Santiago et al. Trials           (2020) 21:17 Page 14 of 14
